Explore the revolutionary advancements in next-generation antibody-drug conjugates (ADCs) for cancer therapy, including bispecific ADCs, novel payloads, and AI-driven development.
Discover ALTA-2618, a revolutionary precision cancer therapy that selectively targets AKT1 E17K mutations while sparing healthy cells.
Explore the revolutionary advances in cancer chemotherapy including precision oncology, immunotherapy 2.0, and AI-driven treatment optimization in 2025.